Colistin in the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical.

[1]  Wen-Sen Lee,et al.  New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship , 2019, Drugs.

[2]  C. Mussini,et al.  Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. , 2019, International journal of antimicrobial agents.

[3]  T. Calandra,et al.  Rational approach in the management of Pseudomonas aeruginosa infections , 2018, Current opinion in infectious diseases.

[4]  Mariana Castanheira,et al.  Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa , 2018, The Journal of antimicrobial chemotherapy.

[5]  J. Li,et al.  Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. , 2018, International journal of antimicrobial agents.

[6]  S. Richter,et al.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Bonomo,et al.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  D. Paterson,et al.  Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients , 2017, Antimicrobial Agents and Chemotherapy.

[9]  A. Oliver,et al.  Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain , 2017, Antimicrobial Agents and Chemotherapy.

[10]  M. Deja,et al.  Therapeutic drug monitoring for colistin therapy in severe multi-resistant Acinetobacter intracerebral abscess: A single case study with high-dose colistin and review of literature , 2017, SAGE open medical case reports.

[11]  J. Li,et al.  Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections , 2017, Antimicrobial Agents and Chemotherapy.

[12]  W. Couet,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin , 2017, Clinical Pharmacokinetics.

[13]  J. Ferreiro,et al.  Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors. , 2017 .

[14]  R. Humphries,et al.  Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3 , 2017, Antimicrobial Agents and Chemotherapy.

[15]  K. Kaye,et al.  Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  S. Luque,et al.  Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa , 2017, BMC Infectious Diseases.

[17]  B. Kreiswirth,et al.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Luque,et al.  Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. , 2016, International journal of antimicrobial agents.

[19]  R. Bonomo,et al.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Turnidge,et al.  Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Turnidge,et al.  New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. , 2015, The Journal of antimicrobial chemotherapy.

[22]  Brian T. Tsuji,et al.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.

[23]  K. Kaye,et al.  Colistin: Understanding and Applying Recent Pharmacokinetic Advances , 2015, Pharmacotherapy.

[24]  S. Zaidi,et al.  Efficacy and safety of low‐dose colistin in the treatment for infections caused by multidrug‐resistant gram‐negative bacteria , 2014, Journal of clinical pharmacy and therapeutics.

[25]  Ronald N. Jones,et al.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). , 2014, Diagnostic microbiology and infectious disease.

[26]  S. Luque,et al.  Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study , 2013, BMC Infectious Diseases.

[27]  F. Puntillo,et al.  High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  W. Couet,et al.  Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80‐mg Intravenous Dose of CMS in Young Healthy Volunteers , 2011, Clinical pharmacology and therapeutics.

[30]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[31]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Turnidge,et al.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. , 2010, The Journal of antimicrobial chemotherapy.

[33]  Yee-Chun Chen,et al.  Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. , 2010, International journal of antimicrobial agents.

[34]  J. Turnidge,et al.  Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models , 2009, Antimicrobial Agents and Chemotherapy.

[35]  M. Sala,et al.  Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections , 2009, Infection.

[36]  A. Armaganidis,et al.  Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[37]  Margaret A Dudeck,et al.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.

[38]  C. Ronco,et al.  The RIFLE criteria and mortality in acute kidney injury: A systematic review. , 2008, Kidney international.

[39]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[40]  J. Turnidge,et al.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.

[41]  Phillip J. Bergen,et al.  Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[42]  R. Bellomo,et al.  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.

[43]  J. Turnidge,et al.  Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. , 2004, The Journal of antimicrobial chemotherapy.

[44]  J. Turnidge,et al.  A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[45]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[46]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[47]  N Klein,et al.  Risk in the "Red Zone": outcomes for children admitted to Ebola holding units in Sierra Leone without Ebola virus disease. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  D. Paterson,et al.  Dosing Guidance for Intravenous Colistin in Critically Ill Patients. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  W. Couet,et al.  Colistin pharmacokinetics: the fog is lifting. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[50]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.